Shots:
- The US FDA has approved Emcitate (tiratricol) for the treatment of peripheral thyrotoxicosis in adults & pediatric pts with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome)
- Approval was supported by an extensive clinical development program assessing Emcitate in pts with MCT8 deficiency, incl. ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Center (EMC) Cohort Study, EMC Survival Study & the US EAP
- Emcitate availability is expected in 8-10wks. post approval. Additionally, the US FDA has granted Egetis a Rare Pediatric Disease PRV, which the company expects to potentially monetize in Q4’26
Ref: Globenewswire | Image: Egetis Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
